Remdesivir Plus Baricitinib Reduces Hospitalized COVID-19 Mortality by 35%
New ACTT-2 data shows a marked benefit from the combination regimen versus lone remdesivir.
Related Articles
Viral Persistence in Semen and Its Implications for Disease Transmission
Sexual transmission was confirmed for nine of the 22 viruses studied, including Ebola, Zika, and mpox, making it a key factor in ongoing disease spread.
NIH: Mutation in Avian Influenza Protein Could Enable Easier Human Infection, But Risk of Infection Remains Low
Jeanne Marrazzo, MD, MPH, director of NIAID, discusses the mutation changes needed to make human-to-human transmission easier as well as infection prevention strategies.
FDA Data on Moderna’s 2 RSV Vaccines for Infants Raise Safety Concerns
The federal agency stated there were cases of RSV lower respiratory tract infection (LRTI) post-immunization for 2 of the company’s vaccines, mRNA-1345 and mRNA-1365.
The Long COVID Patient Journey: A Complex and Unpredictable Experience
Navigating the long road of Long COVID involves more than recovering from an infection; it requires specialized, multifaceted care to address ongoing and often invisible…
WHO Offers Update on Mysterious Disease in Africa
The ongoing outbreak in the Democratic Republic of Congo is affecting mostly very young children, and has investigators searching for answers.
VRE Colonization Linked to Higher Mortality in Sepsis Patients
Study found that VRE colonization is linked to higher mortality, increased need for mechanical ventilation, and renal replacement therapy, while MRSA and C diff colonization…
FDA Grants Breakthrough Designation Status for Test for Patients with Suspected Sepsis
The MeMed Severity test can determine results within 15 minutes through a blood test and aims to offer treatment guidance with machine learning.
Arizona Reports First Human Cases of H5 Avian Influenza
If confirmed by the CDC, these cases would increase the national total of human infections to 60, with 58 already reported in various states.
COVID-19 Therapy Roundtable: What is the Virus Today, Treatment Options, and Addressing the Pediatric Population
In our latest roundtable series, we discuss COVID-19 treatment management and prevention 4 years after the start of the pandemic.
Nirsevimab Reduces RSV Risk in Young Children, but Low Vaccine Uptake Limits Impact
Hospitalization rates for RSV in children under five are comparable to pre-pandemic levels, with the highest rates observed in infants aged 0-2 months.